Tag: mail

PALM BEACH, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- New America Acquisition I Corp. ("NAA" or the "SPAC"), a blank check company targeting businesses with a focus on American values and priorities, announced today that it has filed a registration statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") in connection with a proposed initial public offering of its units. The Florida-based company plans to raise $300 million by offering 30 million units at $10 per unit. Each unit consists of one share of Class A common stock and one-half of a warrant, with each whole warrant exercisable for one share of Class A common stock at $11.50 per share.

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Neogen Corporation (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, inclusive (the “Class Period”), have until Tuesday, September 16, 2025 to seek appointment as lead plaintiff of the Neogen class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, No. 25-cv-00802 (W.D. Mich.), the Neogen class action lawsuit charges Neogen and certain of Neogen’s top executives with violations of the Securities Exchange Act of 1934.

VICTORIA, Seychelles, Aug. 03, 2025 (GLOBE NEWSWIRE) -- A Bitget, principal corretora de criptomoedas e empresa Web3 do mundo, lançou seu novo recurso de compra recorrente, que permite um plano de investimento sistemático, possibilitando aos usuários agendar aquisições automatizadas de criptomoedas usando os cartões Visa e Mastercard. O recurso foi desenvolvido para ajudar os usuários a criarem portfólios de criptomoedas de longo prazo com o mínimo de esforço, aplicando uma estratégia comprovada, conhecida como Dollar Cost Averaging (DCA)  — um método que historicamente gerou retornos de até 30% ou mais em ciclos de mercado em alta.

SAN DIEGO, Aug. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.).

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers’ Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv as well as certain of Fiserv’s top current and former executives with violations of the Securities Exchange Act of 1934.

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), have until September 26, 2025 to seek appointment as lead plaintiff of the Lockheed Martin class action lawsuit. Captioned Khan v. Lockheed Martin Corporation, No. 25-cv-06197 (S.D.N.Y.), the Lockheed Martin class action lawsuit charges Lockheed Martin and certain of Lockheed Martin’s top current and former executives with violations of the Securities Exchange Act of 1934.

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.